We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $542M
1-Year Est. Return 206.64%
This Fund
S&P 500
This Quarter Est. Return
+19.82%
1 Year Est. Return
+206.64%
3 Year Est. Return
+724.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$416M
AUM Growth
+$20.5M
Cap. Flow
-$590K
Cap. Flow %
-0.14%
Top 10 Hldgs %
81.96%
Holding
49
New
14
Increased
9
Reduced
7
Closed
12

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$38.9M
2
INSM icon
Insmed
INSM
+$33.2M
3
VRNA
Verona Pharma
VRNA
+$28.6M
4
TRVI icon
Trevi Therapeutics
TRVI
+$8.16M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$5.96M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$49.9M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$29M
3
ACLX
Arcellx
ACLX
+$15M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$14.9M
5
NUVL
Nuvalent
NUVL
+$6.44M

Sector Composition

Rank Sector Weight
1 Healthcare 93.55%
2 Miscellaneous 6.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
1
DELISTED
Verona Pharma
VRNA
$87.4M 21.03%
924,204
+385,716
+72% +$28.6M
INSM icon
2
Insmed
INSM
$26.9B
$75.8M 18.23%
752,712
+434,473
+137% +$33.2M
ARGX icon
3
argenx
ARGX
$61.9B
$43.2M 10.39%
78,311
+67,000
+592% +$38.9M
SLNO
4
DELISTED
Soleno Therapeutics
SLNO
$41.4M 9.97%
494,424
-4,049
-0.8% -$303K
LLY icon
5
Eli Lilly
LLY
$1.01T
$23.9M 5.76%
30,700
-64,187
-68% -$49.9M
BSX icon
6
Boston Scientific
BSX
$65.7B
$16.7M 4.01%
155,200
+25,500
+20% +$2.58M
MRUS
7
DELISTED
Merus
MRUS
$15.6M 3.76%
296,750
-127,890
-30% -$6.01M
DGX icon
8
Quest Diagnostics
DGX
$25.8B
$14.7M 3.53%
81,717
+25,000
+44% +$4.34M
AZN icon
9
AstraZeneca
AZN
$245B
$13.3M 3.21%
95,376
– –
VRNA
10
PUT
DELISTED
Verona Pharma
VRNA
$8.68M 2.09%
+91,800
New +$6.8M
XBI icon
11
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$8.29M 2%
+100,000
New +$7.98M
TRVI icon
12
Trevi Therapeutics
TRVI
$2.41B
$7.18M 1.73%
+1,311,840
New +$8.16M
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$34.5B
$6.84M 1.65%
20,970
-7,630
-27% -$2.11M
UGL icon
14
CALL
ProShares Ultra Gold
UGL
$872M
$5.82M 1.4%
+168,000
New +$5.83M
REGN icon
15
Regeneron Pharmaceuticals
REGN
$82.6B
$5.6M 1.35%
+10,671
New +$5.96M
SRRK icon
16
Scholar Rock
SRRK
$6.99B
$4.47M 1.08%
126,285
-45,900
-27% -$1.44M
INSM icon
17
CALL
Insmed
INSM
$26.9B
$4.03M 0.97%
+40,000
New +$3.06M
RVMD icon
18
Revolution Medicines
RVMD
$43.9B
$3.83M 0.92%
104,190
– –
SWTX
19
DELISTED
SpringWorks Therapeutics
SWTX
$3M 0.72%
63,930
+10,000
+19% +$445K
EYPT icon
20
EyePoint Inc
EYPT
$391M
$2.98M 0.72%
316,700
– –
ABBV icon
21
AbbVie
ABBV
$438B
$2.69M 0.65%
+14,500
New +$2.69M
VKTX icon
22
Viking Therapeutics
VKTX
$3.93B
$2.56M 0.62%
96,479
+6,200
+7% +$163K
ASND icon
23
Ascendis Pharma A/S
ASND
$17.7B
$2.11M 0.51%
12,240
+4,800
+65% +$782K
TGTX icon
24
TG Therapeutics
TGTX
$8.7B
$1.96M 0.47%
54,515
– –
VRTX icon
25
Vertex Pharmaceuticals
VRTX
$133B
$1.96M 0.47%
+4,400
New +$2.03M
1
2

Similar funds

CA
CV Advisors Aventura, Florida $542M AUM 24.89% 1-Year Est. Return
WCM
Westerly Capital Management San Francisco, California $542M AUM 48.48% 1-Year Est. Return
LI
Louisbourg Investments Dieppe, New Brunswick, Canada $542M AUM 21.44% 1-Year Est. Return
CWWM
Clear Wave Wealth Management Red Bank, New Jersey $541M AUM
FVCM
F&V Capital Management Boca Raton, Florida $542M AUM 46.38% 1-Year Est. Return
LI
Lafayette Investments Ashton, Maryland $542M AUM 22.5% 1-Year Est. Return
CCT
Chemung Canal Trust Elmira, New York $541M AUM 32.42% 1-Year Est. Return
MFS
Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

Artia Global Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Artia Global Partners held 49 positions worth $416M, up 5.2% from $395M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Artia Global Partners's Q2 2025 filing shows 14 new, 9 increased, 7 reduced and 12 closed positions. Its largest new stake was Trevi Therapeutics: 1,311,840 shares worth $7.18M. The largest sale was Eli Lilly, an estimated $49.9M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 86% a quarter earlier, followed by Miscellaneous.

  • Artia Global Partners's largest Q2 2025 buy was Trevi Therapeutics: 1,311,840 shares worth $7.18M.
  • Artia Global Partners added most to argenx in Q2 2025, an estimated $38.9M increase.
  • Artia Global Partners's biggest Q2 2025 reduction was Eli Lilly, cutting an estimated $49.9M.
  • Artia Global Partners fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $29M.
  • Artia Global Partners's ten largest holdings make up 82% of its $416M portfolio in Q2 2025.
  • Artia Global Partners opened 14 new positions and closed 12 in Q2 2025.
  • Artia Global Partners's portfolio value rose 5.2% quarter-over-quarter to $416M.

Based on Artia Global Partners's 13F filing for Q2 2025, filed 14 Aug 2025.